Objective: To study the clinical efficacy of Liu Junzitang and its effect on lung function

exercise tolerance and blood gas analysis in patients with chronic obstructive pulmonary disease (COPD) with symptoms of lung and spleen deficiency at stable stage. Method: A total of 106 cases of patients with COPD at stable stage treated in our hospital were selected and divided into two groups by the random number table

with 53 cases in each group. Patients in both groups were treated with salmeterol and fluticasone propionate powder for inhalation

while treatment group was additionally given Liu Junzitang. The course of treatment was 12 weeks. Then

the changes in lung function

exercise tolerance

respiratory muscle fatigue

values of serum-BNP and inflammatory mediators in two groups were compared. Result: In terms of clinical efficacy

compared with control group (83.02%)

treatment group showed the total effective rate of 96.23%. There was a significant increase (P<0.05). In effect on lung function

forced expiratory volume in the first second (FEV1)

forced vital capacity (FVC) and FEV1/FVC showed no difference between two groups. There were significant differences between two groups of patients before and after 4

12 weeks treatment (P<0.05) in FEV1

FVC and FEV1/FVC improvement. And the values of FEV1

FVC and FEV1/FVC in treatment group is superior to those of control group (P<0.05). Regarding exercise tolerance (6 mWD)

the value of 6 mWD before treatment between two groups showed no difference. There were significant differences between two groups of patients before and after 4

12 weeks treatment (P<0.05). And the value of 6 mWD in treatment group was superior to that of control group (P<0.05). In terms of blood gas analysis (PaO2

SaO2

PaCO2)

there were significant differences between two groups of patients before and after 4

12 weeks treatment (P<0.05). And the values of PaO2

SaO2

PaCO2 in treatment group were superior to those of control group (P<0.05). The value of serum-BNP before treatment between two groups showed no difference. There were significant differences between two groups of patients before and after 4

12 weeks treatment (P<0.05). And the value of serum-BNP in control group was superior to that in treatment group. In terms of inflammatory mediators

values of IL-6

IL-8 and hs-CRP before treatment between two groups showed no difference. There were significant differences between two groups of patients before and after 4 and 12 weeks treatment (P<0.05). And the values of IL-6

IL-8 and hs-CRP in control group were superior to those in treatment group. Conclusion: Liu Junzitang has a good therapeutic effect on COPD with symptoms of lung and spleen deficiency at the stable stage. Liu Junzitang can significantly improve lung function and exercise tolerance

and relieve inflammatory reaction.